News

Catch up on a weekend full of clinical pearls from the 2024 Fall Clinical Dermatology Conference for PAs and NPs in Scottsdale, Arizona.

Dermatology Times asked our readers to share what conferences they are looking forward to in the second quarter of 2024.

Catch up on coverage from the last day of the 2024 Fall Clinical Dermatology Conference for PAs and NPs in Scottsdale, Arizona.

Jason Hawkes, MD, MS, detailed each of the kinases' association with different cytokine receptors and biological functions.

James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.

Lockshin shared his approach to continuing biologic therapies into pregnancy with informed timing adjustments.

Jason Hawkes, MD, MS, breaks down boxed warning pros and cons and research addressing several boxed warnings.

The country's only double-board certified pediatric and cosmetic dermatologist shared what he learned from 5 unique patient cases this year.

James Song, MD, addressed current challenges in the AD treatment landscape and compared biologics.

Jason Hawkes, MD, MS, gives an overview of what clinicians need to know today about this rare condition.

Raj Chovatiya, MD, PhD, focused on understanding JAK inhibitors, discussing their clinical use and safety profiles for effective patient communication.

Catch up on coverage from the second day of the 2024 Fall Clinical Dermatology Conference for PAs and NPs in Scottsdale, Arizona.

Keep up with the latest headlines in dermatology from the past week, including US sunscreen versus global regulations, all-time high melanoma rates in the UK, and more.

Marc Serota, MD, provided clinical pearls to consider for patients on biologics, particularly dupilumab.

Raj Chovatiya, MD, PhD, takes a deep dive in the challenges, solutions, and further research needed to treat seborrheic dermatitis.

James Song, MD, discusses the current treatment landscape, genetic and immunological influences, and the role of oral minoxidil in alopecia areata.

Ben Lockshin, MD, FAAD, delves into the new generation of oral psoriasis therapies to enhance patient quality of life.

The trial results indicated 3 significant improvements across all AHFD subtypes with dupilumab treatment compared to placebo.

Catch up on coverage from the first day of the 2024 Fall Clinical Dermatology Conference for PAs and NPs in Scottsdale, Arizona.

Improvements persisted through the 12-week post-treatment follow-up, indicating sustained efficacy even after discontinuation of dupilumab.

Four leaders in HS treatment and care put a spotlight on the latest clinical trial data and treatment techniques.

Terry Arnold, PA-C, shared his journey and advice for PAs and NPs looking to transition out of a clinical practice.

Significant improvements were observed in EASI scores across all anatomical regions, regardless of patient age or specific body region.

Earlier this week, we shared our fourth and final Skin Cancer Awareness Month quiz. Review the answers and your responses below.

Dermatology Times is looking back on the top stories in dermatology from the month of May.

Dermatology Times will bring clinical insights from leading experts in numerous dermatology specialties.

Novartis announced late-breaking data for the BTK inhibitor at the 2024 European Academy of Allergy and Clinical Immunology Congress.

Raj Chovatiya, MD, PhD, reviews the varying degrees of influence of skin barrier disruption, immune dysregulation, and Malassezia yeast in seborrheic dermatitis.

The phase 2 study achieved the primary end point of a >30% Severity of Alopecia Tool score improvement.

Dermatology Times is recapping our top expert interviews from the month of May.